Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2489-2502

  Schilit, Sara ^a   Benzeroual, Kenza E ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

blocker; 1A adrenergic receptor antagonist; benign prostatic hyperplasia; KMD 3213; selective; silodosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DOXAZOSIN; ERYTHROMYCIN; ITRACONAZOLE; KETOCONAZOLE; PLACEBO; PRAZOSIN; PROTEINASE INHIBITOR; RAPAFLO; SILDENAFIL; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; VERAPAMIL; ADRENERGIC RECEPTOR ALPHA(1A); ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CHO CELL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; HUMAN; INTRAOPERATIVE FLOPPY IRIS SYNDROME; IRIS DISEASE; LOOSE FECES; LOWER URINARY TRACT SYMPTOM; MALE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIAPISM; PROSTATE HYPERTROPHY; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; RETROGRADE EJACULATION; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; SYNCOPE; THIRST; TINNITUS; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; ADULT; AGED; ANIMAL; DOG; DRUG INTERACTION; DRUG POTENTIATION; ECONOMICS; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DOGS; DRUG INTERACTIONS; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 74549116864     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.024     Document Type: Article

References (35)

1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 170 (2003) 530-547
2. Wasserman N.F. Benign prostatic hyperplasia: A review and ultrasound classification. Radiol Clin North Am. 44 (2006) 689-710
3. Thorpe A., and Neal D. Benign prostatic hyperplasia [published correction appears in Lancet. 2003;362:496]. Lancet 361 (2003) 1359-1367
4. Roehrborn C.G., and McConnell J.D. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell-Walsh Urology. 9th ed. (2007), WB Saunders, Philadelphia, Pa
5. Emberton M., Cornel E.B., Bassi P.F., et al. Benign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical management. Int J Clin Pract. 62 (2008) 1076-1086
6. Fine S.R., and Ginsberg P. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: Issues and potential complications. J Am Osteopath Assoc. 108 (2008) 333-337
7. Beduschi M.C., Beduschi R., and Oesterling J.E. Alpha-blockade therapy for benign prostatic hyperplasia: From a nonselective to a more selective alpha1A-adrenergic antagonist. Urology 51 (1998) 861-872
8. O'Leary M.P. Lower urinary tract symptoms/benign prostatic hyperplasia: Maintaining symptom control and reducing complications. Urology 62 Suppl 1 (2003) 15-23
9. Edwards J.L. Diagnosis and management of benign prostatic hyperplasia. Am Fam Physician 77 (2008) 1403-1410
10. Schwinn D.A., and Roehrborn C.G. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 15 (2008) 193-199
11. Rapaflo (silodosin) [package insert] (2009), Watson Pharmaceuticals, Inc, Corona, Calif
12. Schwinn D.A. The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 88 Suppl 2 (2001) 27-34
13. Kawabe K. Current status of research on prostate-selective alpha 1-antagonists. Br J Urol. 81 Suppl 1 (1998) 48-50
14. Lowe F.C. Role of the newer alpha1-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 26 (2004) 1701-1713
15. Murata S., Taniguchi T., Takahashi M., et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol. 164 (2000) 578-583
16. Shibata K., Foglar R., Horie K., et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: Characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 48 (1995) 250-258
17. Akiyama K., Hora M., Yamagishi R., and Kitazawa M. Effects of KMD-3213, a uroselective alpha 1A-adrenoceptor antagonist, on the tilt-induced blood pressure response in normotensive rats. Jpn J Pharmacol. 90 (2002) 131-137
18. Akiyama K., Hora M., Tatemichi S., et al. KMD-3213, a uroselective and long-acting alpha(1a)-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther. 291 (1999) 81-91
19. Akiyama K., Noto H., Nishizawa O., et al. Effect of KMD-3213, an alpha1A-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs. Int J Urol. 8 (2001) 177-183
20. Tatemichi S., Tomiyama Y., Maruyama I., et al. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn. 25 (2006) 792-799
21. Kawabe K., Yoshida M., Homma Y., and Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: Results of a phase III randomized, placebo-controlled, doubleblind study in Japanese men. BJU Int. 98 (2006) 1019-1024
22. Takao T., Tsujimura A., Kiuchi H., et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol. 15 (2008) 992-996
23. Marks L.S., Gittelman M.C., Hill L.A., et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies. J Urol. 181 (2009) 2634-2640
24. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 97 Suppl 2 (2006) 34-38
25. Kobayashi K., Masumori N., Hisasue S., et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J Sex Med. 5 (2008) 2185-2190
26. Gittelman M.C., Hill L., Volinn W., and Hoel G. Safety of silodosin, a highly uroselective alpha-1 adrenergic receptor antagonist: Combined results from an open-label extension of 2 randomized, placebo-controlled, parallel-group studies. Presented at: Annual Meeting of the New England Section of the American Urological Association. Rio Grande, Puerto Rico (2008) Abstract 32
27. Cantrell M.A., Bream-Rouwenhorst H.R., Steffensmeier A., et al. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 42 (2008) 558-563
28. Chang D.F., Braga-Mele R., Mamalis N., and ASCRS Cataract Clinical Committee. ASCRS White Paper: Clinical review of intraoperative floppy-iris syndrome. J Cataract Refract Surg. 34 (2008) 2153-2162
29. Abdel-Aziz S., and Mamalis N. Intraoperative floppy iris syndrome. Curr Opin Ophthalmol. 20 (2009) 37-41
30. Brogden P.R., Backhouse O.C., and Saldana M. Intraoperative floppy iris syndrome associated with tamsulosin. Can Fam Physician. 53 (2007) 1148
31. Chadha V., Borooah S., Tey A., et al. Floppy iris behaviour during cataract surgery: Associations and variations. Br J Ophthalmol. 91 (2007) 40-42
32. Blouin M.C., Blouin J., Perreault S., et al. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: Comparison of tamsulosin and alfuzosin. J Cataract Refract Surg. 33 (2007) 1227-1234
33. Oshika T., Ohashi Y., Inamura M., et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol. 143 (2007) 150-151
34. Red Book: Pharmacy's Fundamental Reference. 2009 Edition (2009), Thomson Healthcare, Montvale, NJ
35. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). Chapter 3: Results of the treatment outcomes analyses. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/chapt_3_appendix.pdf Accessed February 2, 2009